Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children ; volume:14 ; number:1 ; day:1 ; month:12 ; year:2023 ; pages:1-13 ; date:12.2023
Nature Communications ; 14, Heft 1 (1.12.2023), 1-13, 12.2023
- Urheber
-
Bellusci, Lorenza
Grubbs, Gabrielle
Sait, Shaimaa
Yonker, Lael M.
Randolph, Adrienne G.
Novak, Tanya
Kobayashi, Takuma
Khurana, Surender
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-43152-y
- URN
-
urn:nbn:de:101:1-2024022110203180639457
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bellusci, Lorenza
- Grubbs, Gabrielle
- Sait, Shaimaa
- Yonker, Lael M.
- Randolph, Adrienne G.
- Novak, Tanya
- Kobayashi, Takuma
- Khurana, Surender
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry